KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Operating Margin (2016 - 2025)

Historic Operating Margin for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 38.81%.

  • Pfizer's Operating Margin rose 33100.0% to 38.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.55%, marking a year-over-year increase of 507000.0%. This contributed to the annual value of 27.98% for FY2024, which is 175600.0% up from last year.
  • As of Q3 2025, Pfizer's Operating Margin stood at 38.81%, which was up 33100.0% from 34.48% recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Operating Margin peaked at 47.01% during Q3 2022, and registered a low of 410.16% during Q4 2023.
  • In the last 5 years, Pfizer's Operating Margin had a median value of 35.6% in 2021 and averaged 22.31%.
  • In the last 5 years, Pfizer's Operating Margin tumbled by -2380700bps in 2023 and then surged by 2331600bps in 2024.
  • Over the past 5 years, Pfizer's Operating Margin (Quarter) stood at 32.77% in 2021, then surged by 39bps to 45.45% in 2022, then tumbled by -1002bps to 410.16% in 2023, then surged by 109bps to 35.5% in 2024, then grew by 9bps to 38.81% in 2025.
  • Its Operating Margin was 38.81% in Q3 2025, compared to 34.48% in Q2 2025 and 36.15% in Q1 2025.